



# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

### Product identifier

**Product Name** Anti-SARS-CoV-2 Spike Protein S1 Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)

### Other means of identification

**Catalog Number** 100-0583 100-0584

**Document Number** 10000009169

**Synonym** None

### Recommended use of the chemical and restrictions on use

**Recommended Use** Laboratory reagent

### Details of the supplier of the safety data sheet

#### Manufacturer/Supplier

STEMCELL Technologies Canada Inc.  
Suite 500 - 1618 Station Street  
Vancouver, British Columbia V6A 1B6 Canada

#### Emergency telephone number

**Emergency Telephone** 1-800-667-0322

## 2. HAZARDS IDENTIFICATION

### Classification

This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

### Hazards not otherwise classified (HNOC)

Not applicable

### Label elements



# SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

Revision Date 28-Aug-2023

Revision Number 1.1

## Hazard statements

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

The product contains no substances which at their given concentration, are considered to be hazardous to health.

**Appearance** Clear

**Physical state** Liquid

**Odor** No data available

## Other Information

Not Applicable

### **Unknown acute toxicity**

0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### Substance

Not applicable.

### Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

\*The exact percentage (concentration) of composition has been withheld as a trade secret.

## 4. FIRST AID MEASURES

### Description of first aid measures

#### **Inhalation**

Remove to fresh air.



# SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

Revision Date 28-Aug-2023

Revision Number 1.1

<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Wash skin with soap and water.
<b>Ingestion</b>	Clean mouth with water and drink afterwards plenty of water.

## Most important symptoms and effects, both acute and delayed

**Symptoms** No information available.

## Indication of any immediate medical attention and special treatment needed

**Note to physicians** Treat symptomatically.

## 5. FIRE-FIGHTING MEASURES

<b>Suitable Extinguishing Media</b>	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
<b>Unsuitable extinguishing media</b>	CAUTION: Use of water spray when fighting fire may be inefficient.
<b>Specific hazards arising from the chemical</b>	No information available.
<b>Explosion data</b>	
<b>Sensitivity to Mechanical Impact</b>	None.
<b>Sensitivity to Static Discharge</b>	None.
<b>Special protective equipment for fire-fighters</b>	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal precautions, protective equipment and emergency procedures

**Personal precautions** Ensure adequate ventilation.

### Environmental precautions

**Environmental precautions** See Section 12 for additional Ecological Information.



# SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

Revision Date 28-Aug-2023

Revision Number 1.1

## Methods and material for containment and cleaning up

<b>Methods for containment</b>	Prevent further leakage or spillage if safe to do so.
<b>Methods for cleaning up</b>	Pick up and transfer to properly labeled containers.
<b>Prevention of secondary hazards</b>	Clean contaminated objects and areas thoroughly observing environmental regulations.

## 7. HANDLING AND STORAGE

### Precautions for safe handling

**Advice on safe handling** Handle in accordance with good industrial hygiene and safety practice.

### Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store in accordance with information listed on the Product Information Sheet (PIS).

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Control parameters

**Exposure Limits** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

### Appropriate engineering controls

**Engineering controls** Showers  
Eyewash stations  
Ventilation systems.

### Individual protection measures, such as personal protective equipment

**Eye/face protection** No special protective equipment required.

**Skin and body protection** No special protective equipment required.



# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

**Respiratory protection** No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

### Information on basic physical and chemical properties

**Physical state** Liquid  
**Appearance** Clear  
**Color** No information available  
**Odor** No data available  
**Odor threshold** No data available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility in other solvents	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No data available	
Oxidizing properties	No information available	

### Other Information

**Softening point** No information available  
**Molecular weight** No information available  
**Molecular formula** No information available  
**VOC Content (%)** No information available  
**Liquid Density** No information available



# SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

Revision Date 28-Aug-2023

Revision Number 1.1

**Bulk density** No information available

## 10. STABILITY AND REACTIVITY

**Reactivity** No information available.

**Chemical stability** Stable under recommended transport or storage conditions.

**Possibility of hazardous reactions** None under normal processing.

**Conditions to avoid** None known based on information supplied.

**Incompatible materials** None known based on information supplied.

**Hazardous decomposition products** None known based on information supplied.

## 11. TOXICOLOGICAL INFORMATION

### Information on likely routes of exposure

#### Product Information

**Inhalation** Specific test data for the substance or mixture is not available.

**Eye contact** Specific test data for the substance or mixture is not available.

**Skin contact** Specific test data for the substance or mixture is not available.

**Ingestion** Specific test data for the substance or mixture is not available.

### Symptoms related to the physical, chemical and toxicological characteristics

**Symptoms** No information available.

### Numerical measures of toxicity

#### Acute toxicity

**Unknown acute toxicity** 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)



# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)  
Product Information

**Delayed and immediate effects as well as chronic effects from short and long-term exposure**

**Skin corrosion/irritation** No information available.  
Product Information

**Serious eye damage/eye irritation** No information available.  
Product Information

**Respiratory or skin sensitization** No information available.  
Product Information

**Germ cell mutagenicity** No information available.  
Product Information

**Carcinogenicity** No information available.

**Reproductive toxicity** No information available.  
Product Information

**STOT - single exposure** No information available.  
Product Information

**STOT - repeated exposure** No information available.  
Product Information

**Aspiration hazard** No information available.

**12. ECOLOGICAL INFORMATION**

**Ecotoxicity** Product Information

**Persistence and degradability** No information available.

**Bioaccumulation** There is no data for this product.

**Other adverse effects** No information available.



# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

## 13. DISPOSAL CONSIDERATIONS

### Waste treatment methods

**Waste from residues/unused products** Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

**Contaminated packaging** Do not reuse empty containers.

## 14. TRANSPORT INFORMATION

**DOT** Not regulated

**TDG** Not regulated

**MEX** Not regulated

**ICAO (air)** Not regulated

**IATA** Not regulated

**IMDG** Not regulated

**RID** Not regulated

**ADR** Not regulated

**ADN** Not regulated

## 15. REGULATORY INFORMATION

### International Inventories

<b>TSCA</b>	Complies
<b>DSL/NDSL</b>	Complies
<b>EINECS/ELINCS</b>	Complies
<b>ENCS</b>	Does not comply
<b>IECSC</b>	Complies
<b>KECL</b>	Complies
<b>PICCS</b>	Complies
<b>AICS</b>	Complies





# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

## 100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1 Receptor Binding Domain Antibody, Clone Covi-1 (Blocking/Recombinant)

---

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

### US Federal Regulations

#### **SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

#### **SARA 311/312 Hazard Categories**

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

#### **CWA (Clean Water Act)**

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

#### **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

### US State Regulations

#### **California Proposition 65**

This product does not contain any Proposition 65 chemicals.

### U.S. State Right-to-Know Regulations



# SAFETY DATA SHEET

Revision Date 28-Aug-2023

Revision Number 1.1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1  
Receptor Binding Domain Antibody, Clone Covi-1  
(Blocking/Recombinant)**

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water 7732-18-5	-	-	X
Sodium Phosphate Dibasic 7558-79-4	X	X	X

**U.S. EPA Label Information**

**EPA Pesticide Registration Number** Not applicable

**16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION**

**Prepared By,** Quality Control. STEMCELL Technologies Canada Inc.

**Revision Date** 28-Aug-2023

**Revision Note** No information available.

**Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

**End of Safety Data Sheet**